C5 Lenalidomide
CAS No.: 191732-70-4
Cat No.: BP-502133
Purity: ≥95%
4.5 
C5 Lenalidomide is a lenalidomide CRBN-binding scaffold that can serve as a starting point for PROTAC functionalization. Structurally, it retains the characteristic glutarimide and isoindolinone pharmacophores of lenalidomide, including its amino substituent; the listed structure does not contain an appended linker segment. In targeted protein degradation, this type of module is used to recruit the E3 ubiquitin ligase substrate receptor cereblon (CRBN) and to bring the recruited E3 in proximity to the target protein bound by the partner ligand, thereby facilitating ubiquitination and subsequent proteasomal degradation. Its value for targeted degradation research lies in providing a chemically tractable, modular scaffold for assembling PROTACs with tunable linker length and geometry, which are key determinants of ternary complex formation, degradation potency, and selectivity.
Structure of 191732-70-4
Assurance
Delivery
Support
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
- Comprehensive PROTAC Platform
- Scientific Expertise & Technical Support
- Custom Synthesis & Design Service
- Extensive Product Coverage
- Cutting-Edge Innovation
- Fast Delivery & Global Support
- 24/7 customer service
- 100% quality assurance
Popular Publications Citing BOC Sciences Products
This PROTAC linker, C5 Lenalidomide, is designed to serve as a chemically defined connector compatible with targeted protein degradation workflows. Its structural features support efficient conjugation to ligands used for recruiting E3 ligases, enabling formation of PROTAC architectures that promote proximity-driven ubiquitination and subsequent proteasomal degradation. The linker’s suitability for modular synthesis helps researchers tune linker presentation and maintain productive ternary complex formation. Detailed structural and reactivity considerations are provided below.
Structure: The linker is built on a substituted glutarimide framework typical of lenalidomide-derived scaffolds, incorporating heteroatoms capable of hydrogen bonding. It contains aromatic and carbonyl functionalities, with stable covalent bonds that support reliable synthetic handling and conjugation. Overall polarity and conformational rigidity influence PROTAC geometry.
Reactivity: C5 Lenalidomide is commonly employed in PROTAC synthesis via derivatization at the designated attachment handle, using standard amide or carbamate-forming coupling strategies depending on the partner functional group. Typical approaches use activated carboxylic acid derivatives or coupling reagents under inert or controlled conditions, with polar aprotic solvents to promote solubility. Mechanistically, covalent bond formation proceeds through acyl activation and nucleophilic substitution, yielding a stable linker-ligand conjugate suitable for downstream PROTAC assembly.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Related Product Recommendations
Please contact us with any specific requirements and we will get back to you as soon as possible.
